The Sanofi/Trans­late team hits the green light on an ear­ly-stage study for their mR­NA Covid-19 vac­cine af­ter see­ing it work in an­i­mals

Sanofi and their mR­NA vac­cine part­ners at Trans­late Bio say they got the pre­clin­i­cal an­i­mal da­ta on the Covid-19 an­ti­bod­ies they were look­ing for, beat­ing out con­va­les­cent serum. And that clears the way to a Phase I/II launch be­fore the end of this year.

The part­ners are well be­hind the lead mR­NA vac­cines from Pfiz­er/BioN­Tech and Mod­er­na, both still in the run­ning to of­fer piv­otal da­ta in the next weeks. But Sanofi is pur­su­ing a va­ri­ety of ap­proach­es to Covid-19, in­clud­ing an al­liance with GSK on a more tra­di­tion­al ap­proach to vac­cine de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER